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Conclusions: The majority of patients with anal carcinoma can
be treated with curative intent using a sphyincter-sparing
approach of radiochemotherapy even with advanced disease.
Challenges to be meet in the future include the prevention of
metastases and tumour recurrences.
doi:10.1016/j.ejcsup.2008.06.043
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Introduction: Colorectal cancer (CCR) is one of the most com-
mon invasive cancer in western countries with 20% of patients
being initially diagnosed with locally advanced or metastatic dis-
ease. In the last decade, remarkable progress have been made in
the treatment of metastatic CCR, owing to the introduction of
drugs targeting epidermal growth factor receptors (EGFR) like
cetuximab. Cetuximab is characterised by a peculiar skin toxicity
including maculo-papular rash, that, when serious, could led
patients to interrupt therapy, since it brings pruritus and deterio-
rates one’s own physical appearance. There is a paucity of studies
on psychological impact of cutaneous disfiguring conditions on
cancer patients, thus it is not known how much skin rash can
affect patients’ psychological well-being.
Methods: Patients affected by advanced CRC and treated with
cetuximab based-therapy entered the trial, if: (1) aged 18–75; (2)
with ECOG: 0–2; and (3) have received a minimum of four cycles
of cetuximab. The following questionnaires were used: The func-
tional assessment of cancer therapy-colorectal (Fact-C) for quality
of life (QoL), and psychological distress inventory (PDI). It was
added a single question about social avoidance ‘I avoid going
out or seeing persons because of my skin toxicity’, on a five-point
likert scale.
Results: Seventy-nine advanced CRC patients were recruited,
aged 33–74 years old (M = 59); 57% men, 43% women, with the fol-
lowing skin toxicity (NCI-2): no rash: 9%; G1: 45%; G2: 28%; G3:
15%; and G4: none (missing 3%). Thirty-two percent of patients
shows psychological distress. To what concerns social avoidance,
22% of patients answered that they did avoid ‘very much’ going
out. The remaining patients did not avoid going out or only ‘in
a certain way’. Social avoidance was not found to correlate to skin
rash, but only to QoL. The correlation between cutaneous rash
and psychological distress was not found also when controlling
for patient’s gender. A significant correlation was found between
patient’s psychological distress and overall quality of life (Pearson
correlation coefficient = 0.67; p < 0.0001).
Discussion: In this sample, cutaneous rash does not negatively
impact psychological distress. Two explanations were found:
firstly, patients with a longer experience in cancer consider skin
rash as part of the physical and psychological sufferance for can-
cer. Secondly, patients are encouraged by oncologists to carry on
with treatment, because of a possible correlation between skin
rash and illness’ response. This expectation helps patients to find
a meaning in bearing side effects: personal meaning is related to
lower psychological distress because of the heightened sense of
control on a specific event.
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